119-HR-3492 Investigative Journalist Impact Analysis

Summary

What the bill does. H.R. 3492 amends 18 U.S.C. §116 to criminalize, at the federal level, specified surgeries and medications provided to minors for the purpose of changing secondary sex characteristics (defined as “genital or bodily mutilation” and “chemical castration”), punishable by up to 10 years’ imprisonment. It preserves and broadens FGM provisions (e.g., facilitation/consent), adds extensive interstate‑commerce jurisdiction, prohibits prosecuting the minor, and carves out limited exceptions (e.g., certain DSD conditions; excludes mental/behavioral health as a justification). The House passed the measure on December 17, 2025; it is now before the Senate Judiciary Committee. [1]Congress.gov — Text — H.R.3492 (119th): Protect Children’s Innocence Act[2]Congress.gov — H.R.3492 (119th): Bill overview, actions, and status

Context. Current federal law already criminalizes FGM with explicit commerce‑clause elements (STOP FGM Act of 2020). H.R. 3492 would extend the statute’s reach to a wider set of procedures and drugs used for gender‑related treatment in minors. [3]Congress.gov — STOP FGM Act of 2020 (H.R.6100) — Enrolled text[4]LII / Cornell Law School — 18 U.S.C. §116 — Female genital mutilation (codified…

Economic Effects

• Provider exposure and compliance costs: Physicians, hospitals, and telehealth platforms face new felony risk, necessitating legal review, credentialing changes, documentation controls, EHR hard stops, and coverage‑policy alignment; similar criminal frameworks under §116 for FGM establish enforceable commerce‑clause hooks that federal prosecutors could use. [4]LII / Cornell Law School — 18 U.S.C. §116 — Female genital mutilation (codified…
• Demand shock for pediatric gender‑care lines: National claims data indicate that gender‑affirming surgeries among minors were rare even before recent state bans (e.g., 2.1 per 100,000 for ages 15–17 in 2019; none under 12), with nearly all minor surgeries being chest‑related. A federal criminal prohibition would likely drive volumes toward zero in covered categories, reducing related hospital/ASC revenues and ancillary services. [6]JAMA Network Open — Prevalence of Gender‑Affirming Surgical Procedures Among Mi…
• Broader surgical market context: Across all ages, an estimated 48,019 gender‑affirming surgeries occurred in 2016–2020; minor patients (12–18) comprised 7.7%. This contextualizes potential supplier‑side revenue exposure as concentrated in a small share of total GAS volume. [7]JAMA Network Open — National Estimates of Gender‑Affirming Surgery in the US (2…
• Pharmaceutical sales impact: GnRH analogues and related agents often list at thousands of dollars per dose (e.g., Lupron Depot 11.25 mg 3‑month kits typically list in the ~$5,000 range; pediatric 30 mg kits list above ~$12,000), implying material lost revenue for manufacturers and specialty pharmacies serving minors if usage is curtailed. [13]Drugs.com — Lupron Depot — Drugs.com price guide (various strengths)[14]RxSaver — Lupron Depot‑Ped (3‑Month) — RxSaver coupon prices
• Payers and public programs: Passage would interact with a shifting federal policy environment in which HHS has proposed restricting Medicare/Medicaid participation and coverage for providers offering gender‑affirming care to minors; alignment would reduce claims outlays but increase appeals/administrative burden. [15]Reuters — Reuters — HHS proposes rules to cut access to gender‑affirming care f…[16]Washington Post — Washington Post — HHS to revoke funding from hospitals offeri…
• Household spending and mobility: Families already report out‑of‑state travel, medication, and lodging costs when state bans limit access; a federal criminal overlay would likely magnify travel/relocation burdens for those seeking care via research protocols or adult‑age transition. [17]Human Rights Watch — Human Rights Watch — “They’re Ruining People’s Lives”: Ban…

Social Effects

• Population affected: Recent estimates suggest about 724,000 U.S. youths (13–17) identify as transgender (roughly 3.3% of youth), while a much smaller subset seek medical interventions before age 18. [18]UCLA Williams Institute — How Many Adults and Youth Identify as Transgender in…
• Access landscape: As of November 24, 2025, 27 states have enacted laws/policies limiting youth access to gender‑affirming care, with about 50% of trans youth living under such restrictions; a federal criminal statute would supersede pro‑access state regimes and standardize prohibitions nationwide. [5]KFF — Policy Tracker: Youth Access to Gender‑Affirming Care (updated Nov. 24, 2…
• Clinical evidence and guidelines diverge: Major U.S. medical bodies (AAP; Endocrine Society) support access within cautious, multi‑disciplinary protocols; a 2022 prospective study associated initiation of puberty blockers/hormones with reduced depression and suicidality over 12 months. Conversely, the UK’s NHS—following the 2024 Cass Review—ended routine puberty‑blocker prescribing for minors and is shifting to a more research‑delimited, holistic model citing low‑certainty evidence. [8]American Academy of Pediatrics (AAP News) — AAP reaffirms policy and commission…[19]Web search · turn 11 #0[10]NHS England — NHS England — Response to final Cass Review (Apr. 10, 2024)
• Utilization baseline: Claims‑based analyses show minor surgeries were uncommon and overwhelmingly chest‑related in 2019; federal criminalization would primarily affect pharmacologic care (puberty suppression, adolescent hormones) and chest surgery access, not a large volume of pediatric genital surgery. [6]JAMA Network Open — Prevalence of Gender‑Affirming Surgical Procedures Among Mi…
• Equity considerations: Travel and cost burdens from existing bans fall disproportionately on low‑income and rural families; nationalization of criminal penalties may intensify disparities in continuity of care and mental‑health outcomes among transgender youth. [17]Human Rights Watch — Human Rights Watch — “They’re Ruining People’s Lives”: Ban…

Environmental Effects

Direct environmental impacts appear negligible. The bill would reduce certain pharmaceutical and surgical utilization by minors, slightly lowering associated medical waste and drug dispensing volumes; no material long‑run ecological effects are documented in the legislative record or major analyses reviewed.

Temporal Analysis

• Immediate (0–12 months post‑enactment): Rapid cessation of covered procedures for minors by most providers; payer policy adjustments; DOJ/US Attorneys’ Offices develop enforcement guidance; litigation filed in multiple circuits; families shift to wait‑until‑18 strategies or out‑of‑country research protocols. [1]Congress.gov — Text — H.R.3492 (119th): Protect Children’s Innocence Act[5]KFF — Policy Tracker: Youth Access to Gender‑Affirming Care (updated Nov. 24, 2…
• Near term (1–3 years): Coverage denials consolidate; specialty clinics restructure or exit pediatric lines; measurable declines in minor prescriptions of GnRH analogues and adolescent hormones; potential uptick in unregulated sourcing; increased cross‑state travel for psychosocial care. [15]Reuters — Reuters — HHS proposes rules to cut access to gender‑affirming care f…
• Long term (3+ years): National legal baseline interacts with Supreme Court precedent upholding state‑level bans (United States v. Skrmetti, June 18, 2025), reducing the likelihood that federal prohibitions are invalidated on equal‑protection grounds, while leaving room for challenges on other theories (e.g., vagueness, preemption conflicts with research protocols). [12]CNBC — Supreme Court upholds Tennessee ban on transgender youth medical care (U…[20]American Constitution Society — ACS SCOTUS Watch — Summary of U.S. v. Skrmetti…

Unintended Consequences (Risk Register)

• Provider flight and service closures in pediatric endocrinology/adolescent medicine affecting unrelated services (e.g., DSD care), as clinics attempt to ring‑fence legal exposure under a broadened §116. [4]LII / Cornell Law School — 18 U.S.C. §116 — Female genital mutilation (codified…
• Evidence whiplash: Divergent guidance (AAP/Endocrine Society supporting access vs. NHS England’s Cass‑driven restrictions) risks public confusion and politicization, complicating informed consent and family decision‑making. [8]American Academy of Pediatrics (AAP News) — AAP reaffirms policy and commission…[9]Endocrine Society — Endocrine Society statement in support of gender‑affirming…[10]NHS England — NHS England — Response to final Cass Review (Apr. 10, 2024)
• Insurance friction: Increased appeals and disputes over indications (e.g., distinguishing central precocious puberty vs. gender dysphoria uses for GnRH analogues) may raise administrative burden and delay appropriate non‑covered uses. [13]Drugs.com — Lupron Depot — Drugs.com price guide (various strengths)
• Research chill: Narrow exceptions could discourage U.S. participation in pediatric trials or longitudinal cohorts, shifting research offshore and slowing evidence generation. [10]NHS England — NHS England — Response to final Cass Review (Apr. 10, 2024)

Assessment

On balance, the bill would standardize nationwide prohibitions with significant legal and operational effects on a small but vulnerable patient group and a limited slice of pediatric service lines. Economic impacts are modest in aggregate but concentrated for certain clinics, pharmacies, and manufacturers. The social impacts are the most consequential—and uncertain—given conflicting evidence assessments across authorities and the Supreme Court’s validation of state‑level bans that will shape litigation over a federal overlay. Overall stance (analytical, not advocacy): neutral. [6]JAMA Network Open — Prevalence of Gender‑Affirming Surgical Procedures Among Mi…[7]JAMA Network Open — National Estimates of Gender‑Affirming Surgery in the US (2…[18]UCLA Williams Institute — How Many Adults and Youth Identify as Transgender in…[5]KFF — Policy Tracker: Youth Access to Gender‑Affirming Care (updated Nov. 24, 2…[12]CNBC — Supreme Court upholds Tennessee ban on transgender youth medical care (U…

Key Sources

Selected authoritative sources underlying this analysis:

1. H.R. 3492 bill text and status (Congress.gov). [1]Congress.gov — Text — H.R.3492 (119th): Protect Children’s Innocence Act[2]Congress.gov — H.R.3492 (119th): Bill overview, actions, and status
2. Existing federal statute and amendments on FGM (LII; STOP FGM Act of 2020). [4]LII / Cornell Law School — 18 U.S.C. §116 — Female genital mutilation (codified…[3]Congress.gov — STOP FGM Act of 2020 (H.R.6100) — Enrolled text
3. Population estimates (Williams Institute, 2025). [18]UCLA Williams Institute — How Many Adults and Youth Identify as Transgender in…
4. Utilization and surgery trends (JAMA Network Open, 2019 claims; 2016–2020 cohort). [6]JAMA Network Open — Prevalence of Gender‑Affirming Surgical Procedures Among Mi…[7]JAMA Network Open — National Estimates of Gender‑Affirming Surgery in the US (2…
5. U.S. medical‑society positions (AAP; Endocrine Society). [8]American Academy of Pediatrics (AAP News) — AAP reaffirms policy and commission…[9]Endocrine Society — Endocrine Society statement in support of gender‑affirming…
6. NHS England responses and policy following the Cass Review; UK puberty‑blocker restrictions. [10]NHS England — NHS England — Response to final Cass Review (Apr. 10, 2024)[11]UK Department of Health and Social Care — UK Government — Ban on puberty blocke…
7. State policy landscape (KFF Tracker, Nov. 24, 2025). [5]KFF — Policy Tracker: Youth Access to Gender‑Affirming Care (updated Nov. 24, 2…
8. Supreme Court precedent on state bans (U.S. v. Skrmetti), 6/18/2025. [12]CNBC — Supreme Court upholds Tennessee ban on transgender youth medical care (U…[20]American Constitution Society — ACS SCOTUS Watch — Summary of U.S. v. Skrmetti…
9. Drug pricing references for GnRH analogues (Drugs.com; RxSaver). [13]Drugs.com — Lupron Depot — Drugs.com price guide (various strengths)[14]RxSaver — Lupron Depot‑Ped (3‑Month) — RxSaver coupon prices
10. Federal regulatory context (Reuters; Washington Post) on proposed Medicare/Medicaid restrictions. [15]Reuters — Reuters — HHS proposes rules to cut access to gender‑affirming care f…[16]Washington Post — Washington Post — HHS to revoke funding from hospitals offeri…